USAID Approves MedMira's CE Marked Reveal HIV Test
April 04 2012 - 8:30AM
PR Newswire (Canada)
HALIFAX, April 4, 2012 /CNW/ - MedMira Inc., (MedMira) , a
developer of rapid diagnostic technology and solutions, announced
today that the Company's most advanced rapid HIV test, Reveal HIV,
has been approved by the United States Agency for International
Development (USAID) for inclusion on its list of approved rapid HIV
tests. Since its inception in 1986, the USAID HIV/AIDS program has
invested over $7 billion to fight this global crisis. USAID
is a key partner in the U.S. President's Emergency Plan for AIDS
Relief (PEPFAR), the largest and most diverse HIV/AIDS prevention,
care, and treatment initiative in the world. With this approval and
listing, MedMira's CE-marked rapid HIV tests, in addition to the
previously listed FDA-approved rapid HIV test, are eligible for
procurement with funds provided by USAID. This new approval
further strengthens the Company's global rapid HIV test product
line and serves as a strong foundation for MedMira to bring forward
its other rapid diagnostic product lines, including Multiplo, for
similar programs and approvals. "We are very pleased with this
latest approval and MedMira will continue to expand upon its
portfolio of products within organizations such as USAID and PEPFAR
in order to meet the increasing global demand, particularly in
developing countries, for high quality rapid diagnostics," said
Hermes Chan, CEO, MedMira Inc. "With the addition of three
formats of MedMira's CE-marked rapid HIV test, projects funded by
USAID and PEPFAR will be able to select the right format of the
product for their testing initiative and further global HIV
prevention and control efforts." Organizations purchasing Reveal
HIV from the approved USAID list can now select the format and
packaging that best suits their program needs. The various
Reveal HIV product configurations available through USAID offer
customers choice, flexibility and convenience whether their testing
program is taking place in a hospital setting, a voluntary testing
clinic, or through a mobile testing vehicle. Chan continued, "The
Reveal HIV product line satisfies the needs of a broad range of
USAID sponsored testing programs. Resource-constrained
testing programs can use the convenient and cost-effective
all-in-one package for fingerstick, point-of-care testing while
reference laboratories and other clinical settngs can use the
veni-puncture whole blood/serum/plasma formats for batch
testing. The two laboratory formats offer customers
significantly decreased administrative costs and testing time, a
key advantage over other rapid HIV testing technology in large
scale, government screening programs." About MedMira MedMira is a
leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics
and individuals with reliable, rapid diagnosis for diseases such as
HIV and hepatitis C in just three minutes. The company's tests are
sold under the Reveal®, Multiplo™ and Miriad brands in global
markets. MedMira's rapid flow-through HIV test is the only one in
the world to achieve regulatory approvals in Canada, the United
States, China and the European Union. MedMira's corporate offices
and manufacturing facilities are located in Halifax, Nova Scotia,
Canada. For more information visit MedMira's website at
www.medmira.com. This news release contains forward-looking
statements, which involve risk and uncertainties and reflect the
Company's current expectation regarding future events including
statements regarding possible future growth and new business
opportunities. Actual events could materially differ from
those projected herein and depend on a number of factors including,
but not limited to, changing market conditions, successful and
timely completion of clinical studies, uncertainties related to the
regulatory approval process, establishment of corporate alliances
and other risks detailed from time to time in the company quarterly
filings. Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release. MEDMIRA INC. CONTACT: MedMira
Contact:Andrea Young, Corporate CommunicationsTel:
902-450-1588Email: ayoung@medmira.com
Copyright
MedMira (TSXV:MIR)
Historical Stock Chart
From Jul 2024 to Aug 2024
MedMira (TSXV:MIR)
Historical Stock Chart
From Aug 2023 to Aug 2024